Nurix Therapeutics Newsroom

Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?

Yahoo FinanceMay 20 10:21 ET

Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948

TipRanksMay 16 04:17 ET

Nurix Therapeutics Is Maintained at Buy by Stifel

Nurix Therapeutics Is Maintained at Buy by Stifel

Dow JonesMay 15 08:00 ET

Express News | Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target

BenzingaMay 15 07:50 ET

Express News | Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target

BenzingaMay 14 12:04 ET

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)

TipRanksMay 14 11:40 ET

Express News | Nurix Therapeutics Announces Upcoming Oral Presentation of New Data From Ongoing Clinical Trial of Nx-5948, a Selective Bruton’s Tyrosine Kinase (Btk) Degrader, at the European Hematology Association Congress (Eha2024)

ReutersMay 14 10:00 ET

Express News | Nurix Therapeutics Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $20

ReutersMay 14 06:27 ET

Nurix Therapeutics Initiated at Overweight by Stephens & Co.

Nurix Therapeutics Initiated at Overweight by Stephens & Co.

Dow JonesMay 14 06:13 ET

Express News | Stephens & Co. Initiates Coverage On Nurix Therapeutics With Overweight Rating, Announces Price Target of $20

BenzingaMay 14 06:03 ET

Nurix Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 42.76% Stephens & Co. → $20 Initiates Coverage On → Overweight 04/11/2024 64.17% RBC Capital $2

BenzingaMay 14 06:01 ET

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat

GlobeNewswireMay 7 07:00 ET

Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock

$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem

moomoo NewsMay 2 18:43 ET

Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)

TipRanksApr 17 07:21 ET

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nurix Therapeutics (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

GlobeNewswireApr 16 18:21 ET

Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations

TipRanksApr 15 07:11 ET

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 11:34 ET

Express News | Nurix Therapeutics Shares Are Trading Lower After the Company Priced an Upsized Public Offering of 10,166,667 Shares of Common Stock at $15 per Share

Moomoo 24/7Apr 12 09:23 ET

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down more tha

MT NewswiresApr 12 09:16 ET

Sector Update: Health Care

Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down nearly 5

MT NewswiresApr 12 08:54 ET